Pharmaceuticals of the Future Pharmaceuticals of the Future
Pharma Tech Outlook

Pharmaceuticals of the Future

Pharma Tech Outlook | Thursday, December 01, 2022

The impact of innovative medicines on human health has been one of the great achievements of humankind.

FREMONT, CA: One of the greatest accomplishments of humanity has been the effect of novel medications on human health. Smallpox, diphtheria, typhoid, polio, rubella, measles, and mumps were once widespread and frequently fatal diseases, but they are now successfully controlled and frequently eradicated. With the FDA's clearance of the first biotech drug in the US, a genetically modified form of human insulin, a new wave of avant-garde medications was introduced in 1982.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

The biotech sector has since experienced fast expansion, and in 2021, the FDA approved the 100th monoclonal antibody therapy. With a compound annual growth rate of 12 per cent and more than USD 300 billion in global sales, biopharmaceuticals account for around 60 per cent of therapies under research.

Naturally, the public's awareness of biotech innovation was greatly influenced by the world's nervous anticipation for creating vaccinations and antiviral medications during the Covid pandemic. This culminated in the unprecedented accomplishment of developing the first batch of a candidate mRNA vaccine within a remarkably short time following the initial genomic sequencing of the SARs-CoV-2 virus.

A 50,000-step method for developing the mRNA vaccine was developed using numerous supply chain and manufacturing advances. Surprisingly, more than 7 billion doses of various vaccines have been distributed internationally in just 18 months.

Despite these successes, there is still much work to be done. For instance, just five per cent of the more than 7,000 rare diseases that impact more than 300 million people globally have viable treatments.

The Pace of Change

Monoclonal antibodies and recombinant therapeutic proteins have largely been responsible for the influence of biotech medications over the past ten years. The pipeline for new, highly inventive medications is filling up quickly, resulting in an unprecedented range of therapeutic approaches.

In December 2021, there were more than 12,600 projects in clinical development, with roughly 50 per cent of them being for small molecule chemistry products and 50 per cent for biopharma products.

These studies were spread over a variety of therapeutic areas, with oncology accounting for 50 per cent of them, followed by autoimmune diseases (11 per cent), central nervous system (10 per cent), and infectious diseases (7 per cent).

Another 20 per cent of these clinical development programmes are centred on monoclonal antibodies. Included in this are newer, more sophisticated multi-specific antibodies and antibody-drug conjugates (ADCs), which use highly selective monoclonal antibodies combined with other substances like chemotherapy medicines to target particular cells like cancers while preserving neighbouring healthy cells.

In another 4.3 per cent of these efforts, healthy, functional cells are used as the therapy to cure a condition or disease in which the patient's cells are ill or damaged.

Gene-modified cell therapy (348 projects, 2.7 per cent), in which a functional gene is inserted into a cell-based therapy, is particularly interesting. For instance, chimeric antigen receptor T-cell (CAR-T) therapies have shown to be incredibly effective at treating and successfully curing several blood malignancies that were once fatal.

In this personalised medicine, the T-cells are genetically modified and then reinjected back into the donor patient after being purified from the patient's blood cells. The modified T-cells activate the patient's immune system to selectively attack the particular malignancy.

Gene therapies, in which a patient's genes are manipulated to treat or prevent a disease, are one of the most intriguing kinds of treatments now under investigation (281 projects, 2.2pc). RNA treatments, such as antisense medications, obstruct messenger RNA translation and consequently stop the synthesis of specific disease-related proteins.

Oncolytic viruses, in which tumour-seeking viruses infect tumour cells and multiply inside them until the cells burst, release signals that enable the immune system to identify cancer and start an immunological attack on it. The first in-vivo phase 1 study for gene editing (CRISPR-CAS9) was also implemented in 2021.

A new drug must travel a long and arduous path from discovery to clinical testing to patient care. A new treatment takes an average of USD 2.6 billion and more than ten years to create, and just 12 per cent of products that enter clinical trials end up being approved for sale.

To beat these chances, a large amount of risk and money must be invested. For instance, Eli Lilly(NYSE: LLY) spends 25 per cent of its net sales on R&D and has invested enormous sums of money over the past 30 years in the search for Alzheimer's disease treatments.

An emphasis on flexible, agile facilities with the capacity to create a variety of products is pushing fundamental changes in manufacturing facility design, operations, and supply chain due to the diversity in the biotech pipeline.

Although there are many obstacles to overcome, including access to end-to-end high-quality data management from research through manufacturing operations, digitisation can be a fundamental enabler of a competitive manufacturing advantage.

New production process efficiencies, higher quality, and lower costs are still needed to be competitive. Key trends include the following, many of which depend on vendor innovation:

Multi-product, More Adaptable Facilities

Continued usage of single-use systems in clinical and commercial settings. Purification yields and expression titres have steadily increased as host cell lines, culture mediums, expression methods, vectors, promoters, and other factors have improved. Continuous processing, including downstream chromatography and upstream perfusion. Digitalisation and Industry 4.0 implementation, with an emphasis on automation and data analytics.

Biopharma manufacturing uses a lot of energy and water, so it's important to strike a balance between that and a constant focus on environmentally friendly practices.

More in News

Pharmacovigilance refers to the comprehensive process of collecting, monitoring, evaluating, and preventing adverse effects associated with medications and treatments. As a process-driven scientific discipline within the pharmaceutical industry, its core objectives are to implement effective signal detection systems and leverage advanced data analytics to proactively monitor the safety of new drugs across large patient populations, ultimately ensuring safer medication use. Complex international rules, growing data quantities, numerous data sources, broader risk monitoring, and precise patient event recording worldwide are all factors increasing pressure on pharmacovigilance systems to change. Appropriate analytics are essential, but businesses often spend more on data processing than creative research and new technology, leading to less-than-ideal results. Implementing artificial intelligence and embracing emerging technologies throughout the pharmaceutical value chain can have numerous advantages. Here are some ways AI can Help enhance pharmacovigilance: An Expedited Path to the Market Drug development requires a lot of time because pharmaceutical companies benefit from competitive product-to-market lead times, which increase market share and profitability. Solutions utilizing artificial intelligence can facilitate quicker decision-making. Without sacrificing patient safety, a shorter end-to-end drug development cycle translates into a faster route to market. Cost-Effective Processes Pharmaceutical firms have historically used outsourcing or labor offshoring to meet the ever-increasing resource demands and expenses. That's one method of cost reduction. Another option is to invest in custom software solutions for automation and augmentation, which can result in noticeable cost savings and a significant return on investment. The business can lower the price of a product recall or an update to the label.  More accuracy and efficiency in PV services reduce the entire cost of the drug development process. The most significant financial impact on a pharmacovigilance budget is caused by case processing. The most important chance to reduce the expenses associated with the pharmaceutical development process may be to automate the reporting and management of safety cases using machine learning algorithms. Expedited Error-Free Reporting Using artificial intelligence technologies to automate repetitive jobs is a great idea. Human mistakes can be eliminated by automating the time-consuming and expensive direct annotation of source documents, provided that stringent guidelines are followed. The initial centralized medication safety monitoring stage is NLP, which automates safety reporting. Data-Driven Insights for Safety Due to growing data sets and sources, processing pharmacovigilance data solely using expert labor is not feasible. There is an enormous need for simplification, and data science solutions may help by offering predictions, intelligent, valuable insights, and automated analysis. Regulatory Compliance Over the past few years, pharmacovigilance activities have become increasingly expensive for pharmaceutical corporations due to the advent of stricter regulations worldwide. Businesses must continue to adhere to the ever-changing laws in many nations. A digitalized, adaptable architecture supporting the drug development process and global drug monitoring is the solution to being robust. ...Read more
With the introduction of electronic clinical trial management systems, clinical trial administration has substantially transformed. Clinical trial effectiveness and compliance depend on the technologies' promised expedited procedures, enhanced data accuracy, and prompt monitoring. It takes careful thought and smart techniques to navigate the difficulties related to timely monitoring and data accuracy in eClinical trial management. Data quality is crucial in clinical trials since faulty data can result in incorrect results, problems with regulations, and even patient injury. The focused strategy can increase productivity and quickly resolve urgent problems. Human errors during data input can lead to discrepancies and inconsistencies in trial data. Clinical trials often involve complex protocols with numerous variables and endpoints, increasing the risk of data misinterpretation and mistakes during data collection and entry. Implementing automated data capture technologies, like electronic data capture systems and direct data entry from medical devices, can reduce the reliance on manual entry and minimize errors. Automated validation checks can ensure data consistency and accuracy. Standardizing data formats and terminologies across different systems and sources is essential to facilitate seamless integration and minimize the risk of mismatched data. Timely monitoring of clinical trials remains crucial for early issue detection, safeguarding patient safety, and ensuring regulatory compliance . Solara Labs provides analytical and technology-driven solutions that support real-time data integration and monitoring across trial sites. Achieving timely monitoring, however, can be challenging, as delays in data entry, transfer, and processing can impede real-time oversight. Traditional monitoring methods, which rely on periodic data reviews, may postpone the identification and resolution of potential issues. Limited monitoring resources can lead to delayed problem identification and slower response times. Implementing real-time data capabilities allows continuous monitoring and immediate access to up-to-date trial data. Cloud-based systems can facilitate real-time data sharing and access. Utilize centralized monitoring approaches, where data from multiple sites are collected and analyzed in real-time at a central location. This allows for early detection of trends and potential issues. Adopt risk-based monitoring strategies, prioritizing resources and monitoring efforts based on identified risks. Tianyu Pharm enhances clinical trial management by integrating secure data processes and compliance practices across diverse regulatory environments. Maintaining regulatory compliance and ensuring data security are critical challenges in eClinical trial management. Non-compliance can lead to trial delays, fines, and damage to reputation. Different regions have varying regulatory requirements, making compliance complex and challenging. Maintaining comprehensive and tamper-proof audit trails is necessary for regulatory compliance and accountability. Stay informed about regulatory changes and requirements in different regions. Use advanced encryption methods and robust security protocols to protect patient data. Update security measures regularly to combat emerging threats. Ensure detailed and immutable audit trails for all data entries, modifications, and access. This enhances transparency and compliance. Navigating the challenges of data accuracy and timely monitoring in eClinical trial management is crucial for the success of clinical trials. By leveraging advanced technologies, standardizing processes, and adopting strategic monitoring approaches, clinical trial managers can enhance data accuracy, ensure timely monitoring, and maintain regulatory compliance. ...Read more
The journey of a potential new medicine from a laboratory concept to a patient's hands is lengthy, costly, and fraught with risk. For every successful therapeutic that emerges, thousands of promising candidates fall by the wayside, often due to unforeseen safety issues that only become apparent late in the development process. This high attrition rate is the central challenge in pharmaceutical research and development. In response, the industry is undergoing a profound transformation, driven by artificial intelligence, to build a new paradigm of predictive, proactive, and de-risked drug discovery. At the heart of this revolution is the ability to predict the three-dimensional structures of proteins and use this structural knowledge to anticipate and design against a drug's potential for harmful side effects. The Structural Biology Revolution: From Years to Minutes For decades, understanding the precise 3D shape of a protein—the molecular machines of the body—was a monumental task. Techniques like X-ray crystallography and cryo-electron microscopy, while powerful, are slow, labor-intensive, and not consistently successful. This left vast portions of the human "proteome" as uncharted territory for drug designers. The advent of sophisticated AI and deep learning models has shattered this long-standing barrier. These algorithms, trained on the vast repository of known protein structures, can now predict the intricate folded shape of a protein from its linear amino acid sequence with astonishing accuracy and speed. This breakthrough has effectively rendered the entire human proteome structurally visible, creating a comprehensive, high-resolution map of nearly every potential target a drug molecule could interact with inside the body. This newfound clarity is not just accelerating the discovery of therapeutic targets; it is fundamentally changing how the industry approaches drug safety by illuminating the landscape of potential "off-targets." The ideal drug is a molecular "magic bullet" that interacts only with its intended disease-causing target. The reality, however, is that drug molecules can and often do bind to other, unintended proteins. These are known as off-target effects, and they are the primary molecular cause of adverse drug reactions and unforeseen toxicities that can derail a clinical trial or lead to a drug's withdrawal from the market. A drug candidate might be highly effective at engaging its therapeutic target. Still, if it also happens to bind to a crucial protein involved in heart rhythm or liver function, the resulting side effects could be severe. Historically, identifying these off-target liabilities was a slow, reactive process, relying on extensive and often inconclusive cellular and animal testing. This meant that the accurate safety profile of a compound usually remained dangerously obscure until significant investment had already been made. AI-Powered Off-Target Profiling: A New Paradigm for Safety The convergence of AI-predicted protein structures and advanced computational simulation has given rise to a powerful new strategy: proactive, in silico (computer-based) off-target profiling. This approach flips the traditional safety assessment model on its head. Instead of waiting to observe toxicity, researchers can now predict it at the very inception of a drug discovery program. The process begins with a potential drug molecule. Its own 3D structure is either known or can be reliably modeled. This digital representation of the drug is then computationally screened against a vast virtual library containing the AI-predicted structures of thousands of proteins from across the human proteome. Using physics-based algorithms like molecular docking, scientists can simulate the potential interaction between the drug candidate and each of these proteins. These simulations calculate the binding affinity, or the strength of the interaction, between the drug and each potential off-target. The result is a comprehensive off-target profile or selectivity panel that flags any proteins the drug is likely to bind to, aside from its intended target. This provides an unprecedentedly early and detailed view of a compound's potential safety liabilities, long before it is ever synthesized in a laboratory. Reshaping the Drug Discovery Pipeline This ability to foresee off-target interactions allows for a much more effective early-stage triage of drug candidates. Compounds that show a high propensity for binding to known toxicological off-targets can be deprioritized and discarded immediately, allowing research teams to focus their resources on molecules with a cleaner predicted safety profile. It further enables structure-guided safety optimization. When a promising drug candidate is found to have a potential off-target liability, medicinal chemists no longer have to rely on trial and error. By examining the AI-predicted structures of both the intended target and the off-target, they can see precisely how the molecule is binding to each. This insight allows them to rationally redesign the drug, making specific chemical modifications to disrupt the interaction with the off-target protein while preserving or even enhancing its binding to the therapeutic target. This approach helps elucidate the potential mechanism of toxicity. By identifying which off-target pathways are likely to be affected, scientists can form early hypotheses about the nature of possible side effects, guiding more focused and relevant preclinical safety studies. This shift toward a predictive, structurally-informed approach to safety promises to significantly reduce the high rate of late-stage failures, making the path to new medicines faster, more efficient, and fundamentally safer. The pharmaceutical industry, long defined by the precarious balance between therapeutic promise and unforeseen toxicity, is entering a new era of predictive certainty. The convergence of artificial intelligence and structural biology is not merely refining drug development—it is redefining it. By mapping the human proteome in structural detail and using this knowledge to anticipate and eliminate off-target effects in silico, AI is transforming drug safety from a reactive checkpoint into a foundational design principle. This paradigm shift enables the creation of therapeutics engineered with safety and selectivity at their core, dramatically reducing late-stage failures and accelerating the path from discovery to delivery. As AI reshapes the scientific and operational landscape of drug discovery, the journey from lab to clinic is becoming not only faster but also fundamentally safer for patients worldwide. ...Read more
Fueled by rapid technological advancements and a growing focus on patient-centered care, the pharmaceutical industry is increasingly implementing advanced pharmacy management platforms that serve as comprehensive, integrated ecosystems. These platforms streamline workflows, enhance patient safety, and boost operational efficiency across diverse pharmacy settings, from large healthcare systems to local community pharmacies. Foundational Pillars: Core Functionalities and Workflow Optimization Modern pharmacy management administrative platforms are built upon a robust foundation of core functionalities designed to streamline daily operations. Prescription processing remains central, but it has undergone significant evolution. Automated validation systems now meticulously check for correct dosages, potential drug interactions, and patient allergies, considerably reducing the risk of medication errors. This automation extends to inventory and stock management, a critical area for pharmacy profitability and patient access. Advanced systems leverage real-time updates, predictive analytics, and automated reordering capabilities to prevent stockouts and overstocking, ensuring that essential medications are always available while minimizing waste. Billing and documentation, historically time-consuming and error-prone, have also seen substantial improvements. Automated billing solutions generate invoices, apply relevant taxes, and integrate with various payment systems, including options for partial payments. Detailed financial reports provide transparent insights into sales, transactions, and revenue flow, empowering pharmacies to manage their finances more effectively and maintain a sense of control. Beyond these core functions, platforms are increasingly incorporating features like robust patient profiling, enabling personalized dosing regimens and comprehensive medication histories that inform clinical decisions. The Rise of Intelligent Automation and AI Integration A defining characteristic of the current generation of pharmacy management platforms is the pervasive integration of AI and automation. These technologies are not merely augmenting existing processes but are fundamentally reshaping the administrative landscape. AI-powered algorithms analyze vast datasets, including historical sales, market trends, and even seasonal patterns, to provide highly accurate demand forecasting. This capability is instrumental in optimizing inventory and procurement, enabling pharmacies to anticipate medication needs and adjust stocking levels proactively. Automation extends to various repetitive tasks, including automated dispensing systems that accurately sort, count, and package medications, as well as streamlined prescription verification and claims processing. This frees up pharmacy staff from mundane administrative burdens, allowing them to redirect their focus towards higher-value activities such as patient counseling, medication therapy management, and collaborative care initiatives. AI also plays a crucial role in enhancing patient safety through advanced drug allergy detection, real-time medication interaction alerts, and intelligent identification of potential prescription mistakes. Furthermore, AI-driven systems are being developed to simplify complex processes, such as prior authorization, thereby relieving pharmacy staff from additional burdens and accelerating patient access to specialty medications. Interoperability: Connecting the Healthcare Ecosystem Interoperability has emerged as a paramount imperative in modern healthcare, and pharmacy management platforms are at the forefront of this movement. The ability of diverse information systems, devices, and applications to access, exchange, and integrate data seamlessly is crucial for coordinated patient care. Pharmacy platforms are increasingly designed to integrate with broader healthcare ecosystems, including Electronic Health Records (EHRs) and Hospital Management Systems (HMS). This integration ensures that prescriptions from consultations, inpatient care, or self-prescriptions are automatically transferred to the pharmacy, eliminating manual input errors and providing a unified digital environment. Standardization is key to achieving true interoperability—frameworks like HL7 V2 are essential. X and FHIR (Fast Healthcare Interoperability Resources) facilitate the structured exchange of health information, while NCPDP (National Council for Prescription Drug Programs) sets standards specifically for prescription-related data exchange. This seamless flow of information enables pharmacists to gain a comprehensive understanding of a patient's medical history, facilitating more informed decision-making, reducing the likelihood of adverse drug interactions, and improving patient outcomes. The future will see even greater emphasis on robust APIs and data normalization techniques to ensure consistent and reliable data sharing across all stakeholders in the healthcare continuum. Data Analytics: From Information to Insight Modern pharmacy management platforms are evolving beyond simple data collection by leveraging advanced data analytics to generate actionable insights from raw information. This computational analysis of pharmacy operations enables businesses to streamline workflows, enhance service delivery, and improve patient outcomes. By examining critical metrics such as patient adherence, prescription trends, and supplier performance, pharmacies can identify inefficiencies and develop targeted strategies to address them. Key applications of pharmacy data analytics include predictive demand forecasting, where historical data is used to anticipate medication needs and prevent overstocking or shortages, and personalized patient care, which tailors treatment plans based on patient history and behavior, thereby improving adherence and therapeutic outcomes. Operational optimization is achieved by analyzing transaction volumes, peak hours, and seasonal trends to inform staffing and resource allocation decisions. Financial performance is enhanced through tracking sales patterns, identifying high-margin medications, and refining pricing strategies in response to market demand. Analytics support regulatory compliance by automating the monitoring of controlled substances and safeguarding patient data, thereby ensuring adherence to industry standards and regulations. The trajectory of pharmacy management administrative platforms is leading towards an increasingly intelligent, integrated, and patient-centric future. A key aspect of this evolution is the expansion of telepharmacy and remote services, facilitated by platforms that support virtual consultations and medication management from a distance. This trend is particularly beneficial for underserved areas, as it brings much-needed healthcare services to these regions. The future of pharmacy management administrative platforms is about empowering pharmacists to move beyond dispensing and embrace expanded clinical roles. The ongoing evolution of these platforms will continue to redefine the pharmacy's role, making pharmacists an even more integral and intelligent component of the broader healthcare delivery system and underscoring their value in patient care. ...Read more

Weekly Brief